Advertisement
News
Subscribe to MDT Magazine News

Sanofi-aventis CEO Viebacher detaiils strategy post-Genzyme buyout

April 12, 2011 7:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Sanofi-aventis CEO Chris Viebacher outlined the research and development strategy that led to the purchase of Cambridge-based Genzyme Corp. for $20.1 billion and will lead the company to further expand its partnerships and acquisitions.

Alliance HealthCare acquires US Radiosurgery

April 12, 2011 6:45 am | by The Associated Press | Comments

Alliance HealthCare Services has acquired US Radiosurgery LLC for about $43 million in cash, the company said Tuesday.Alliance provides diagnostic imaging and radiation for cancer treatment. US Radiosurgery is based in Nashville, Tenn., and it runs eight radiosurgery centers in eight different...

Use of combination drug regimen for treating TB may represent an effective treatment option

April 12, 2011 6:41 am | by EurekAlert | Comments

(JAMA and Archives Journals) In patients with newly diagnosed tuberculosis, use of a combined 4-drug fixed-dose regimen was found to have comparable outcomes to drugs administered separately, according to a study in the April 13 issue of JAMA, a theme issue on infectious disease...

TOPICS:
Advertisement

Genzyme CEO Termeer joins Aveo board

April 12, 2011 6:40 am | by Mass High Tech: The Journal of New England Technology | Comments

Outgoing Genzyme Corp. chairman, CEO and president Henri A. Termeer has been appointed to the board of directors for Aveo Pharmaceuticals Inc., a Cambridge company focused on cancer therapeutics.

Asante Solutions, Inc. Receives CE Mark for Pearlâ„¢ Insulin Pump

April 12, 2011 6:38 am | by Bio-Medicine.Org | Comments

SUNNYVALE, Calif., April 12, 2011 /- Asante Solutions, Inc. (Asante), a medical device company focused on diabetes care, today announced it received the CE mark for its Pearl Insulin Pump, the only insulin pump that uses a pre-filled insulin cartridge. The CE mark is a European proof of...

TOPICS:

Visual Healthcare to Support Chinese Clinical Trials

April 12, 2011 6:38 am | by Bio-Medicine.Org | Comments

RENO, Nev., April 12, 2011 /- Visual Healthcare Corp. (the "Company") (NASDAQ OTC: VSHC) announces today that work has begun on a Chinese based adaptation of the information technology grid that its clients use in their clinical trial applications. This project has been launched in...

TOPICS:

Study Provides New Means for Classifying E. Coli Bacteria & Testing for Fecal Contamination

April 12, 2011 5:38 am | by Georgia Tech Institute of Technology | Comments

The meaning of the standard fecal coliform test used to monitor water quality has been called into question by a new study that identified sources of Escherichia coli bacteria that might not indicate an environmental hazard.

Lanx®, Inc. Launches Durango™ Stand-Alone ALIF System

April 12, 2011 5:35 am | by Bio-Medicine.Org | Comments

BROOMFIELD, Colo., April 12, 2011 /- Lanx®, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, today announced the initial launch of its Durango™ Stand-Alone ALIF System (Durango), following 510(k)...

TOPICS:
Advertisement

Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial

April 12, 2011 5:35 am | by Bio-Medicine.Org | Comments

ROCKVILLE, Md., April 12, 2011 /- Neuralstem, Inc. (NYSE Amex: CUR ) announced that Eva Feldman, M.D., Ph.D., Principal Investigator of the Phase I safety trial of Neuralstem's human spinal cord stem cells (HSSC) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), and unpaid...

TOPICS:

Lanx®, Inc. Announces Launch of Concero™ Facet Screw System for Spinal Fusion

April 12, 2011 5:35 am | by Bio-Medicine.Org | Comments

BROOMFIELD, Colo., April 12, 2011 /- Lanx ® , Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, today announced the launch of the Concero™ Facet Screw System (Concero) at the 2011 American Association...

TOPICS:

Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results

April 12, 2011 5:35 am | by Bio-Medicine.Org | Comments

WARSAW, Ind., April 12, 2011 /- Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) announced today its first quarter 2011 sales and earnings conference call will be broadcast live over the Internet on Thursday, April 28, 2011, at 8:00 a.m. Eastern Time.  A news release detailing the...

TOPICS:

Q & A: Revamping a Radiology Practice's Revenue Cycle Management

April 12, 2011 5:33 am | by Diagnostic Imaging | Comments

Radiology Associates of South Florida, one of the largest practices in the country based in Miami-Dade County, recently make a major shift in their revenue cycle management. Here, Dennis Wiseman, RASF's executive director, discusses why they changed systems, the challenges they faced, and...

TOPICS:

CMS May Require Some Doctors to Get Pre-Authorization for Imaging

April 12, 2011 5:33 am | by Diagnostic Imaging | Comments

High utilizers of advanced medical imaging beware: the Medicare Payment Advisory Commission (MedPAC) just voted 15-1 this month to recommend to Congress that the top tier of referrers of advanced medical imaging should get prior authorization first.

TOPICS:

Aethlon Medical Announces Multi-Target Exosome Assay Validation

April 12, 2011 5:32 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 12, 2011 /- Aethlon Medical, Inc. (OTCBB: AEMD) announced today that its wholly owned subsidiary Exosome Sciences, Inc. (ESI) has validated the ability of its Enzyme Linked Lectin Specific Assay (ELLSA) to identify the presence of exosomes underlying the human...

TOPICS:

MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology

April 12, 2011 3:33 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., April 12, 2011 /- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the Company will present new data from two safety studies of LEVADEX® orally inhaled migraine drug.  The data will be presented at the 63rd Annual Meeting of the American...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading